Objective: Evaluate the safety and efficacy of OBV/PTV/r + DSV with low-dose RBV (600 mg once daily) for 12 weeks in GT1a HCV-infected patients, naïve or experienced (with pegIFN/RBV), without cirrhosis and compare with the historical SVR12 rate for 3-DAA + full-dose, weight based RBV
Six-month data from a real-world surveillance study shows over-the-counter IBgard is safe and well-tolerated in patients with irritable bowel syndrome, according to a press release from the manufacturer.
A recent randomized clinical trial (RCT) of a novel peppermint oil preparation (PO-SST) demonstrated significant relief of irritable bowel syndrome (IBS) symptoms versus placebo. In addition to efficacy, patient satisfaction and post-marketing utilization are also important to assess.
Functional Dyspepsia (FD), known for its symptoms of persistent or recurring indigestion, impacts an estimated 1 in 6 adults in the U.S. Rapid symptom improvement reported by patients taking FDgard® Patients reported high overall level of satisfaction and enhanced quality of life whil
IBgard® demonstrated to be an effective, safe and well tolerated option to address unmet need for patients with IBS Rapid and symptomatic improvement of the most bothersome gastrointestinal symptoms at 24 hours and at four weeks First clinical trial to use patented Site Specific Targe
IBgard, a new, more purified formulation of IBgard, an over-the-counter medical food containing a blend of L-menthol and peppermint oil, improved IBS symptoms within 4 weeks, according to data presented at the AGA’s 2015 James W. Freston Conference in Chicago. “This single-arm 2015 IB
For IBS patients, current formulations of mint oil may cause heartburn, nausea, and anal burning because they tend to “dose-dump” in the stomach or pass all the way through the colon. However, a novel delivery system (IBgard, IM HealthScience LLC) allows solid beads of highly purified
By Walter Alexander WASHINGTON, D.C. — May 20, 2015 — A novel delivery system that releases peppermint oil into the small intestine demonstrated reduction in the symptoms of irritable bowel syndrome (IBS) when compared with placebo, according to 24-hour results of Irritabl
WASHINGTON — Michael Epstein, MD, senior medical advisor for IMHealthScience, discusses his presentation on IBgard, a new medical food product for the treatment of diarrhea-predominant and mixed-symptom irritable bowel syndrome. According to a press release, IBgard works by delivering